Webcast Teaches Physicians About Advances in Liver Disease

OSU Wexner Medical Center logo Webcast Teaches Physicians About Advances in Liver Disease. Last summer, experts from around the world worked together to rename Nonalcoholic fatty liver disease into Metabolic dysfunction-associated steatotic liver disease or MASLD. And earlier this year at the end of March 2024, the FDA approved the first drug to treat MASLD. Meanwhile another promising agent is already in the pipeline, currently undergoing phase 3 clinical trials.

To share more about the advances in some of the most common liver conditions including MASLD, autoimmune hepatitis, and Hepatocellular carcinoma, We’ve invited one of Ohio State University’s Transplant Hepatology experts. We are pleased to introduce Assistant Professor of Gastroenterology and Hepatology Dr Vivek Mendiratta.

What you’ll learn in this webcast

As a result of this educational activity, webcast participants will be able to:

  • Understand steatotic liver disease including diagnosis, management, and pharmacologic treatment options.
  • Learn about the newest advances in hepatocellular carcinoma including the role of combination therapy, novel biomarkers, and liver transplantation.

You’ll also learn about the following:

  • Treatment & Monitoring
  • Weight Loss
  • Liver Transplantation

You can find this and many other MedNet21 programs on the OSU – CCME website.
Call our MedNet21 Program Manager at 614.293.3473 for more details about subscribing to MedNet21 as a hospital or as an individual. You can also e-mail him at derrick.freeman@osumc.edu.

Get An Update on Advances in Migraine and other Headache Syndromes on Webcast

OSU Wexner Medical Center logo Get An Update on Advances in Migraine and other Headache Syndromes on Webcast. Just within the past few years, there have been several new agents approved by the FDA for both migraine prevention and acute migraine treatment.

Today on MedNet21, we have invited two of Ohio State University’s Neurology experts to review migraines and other common primary headache syndromes and discuss their treatment options including these new agents. I am so pleased to introduce Drs. Ana Verdecia and Kevin Weber. Ana and Kevin are both fellowship trained in Headache Medicine and Kevin also serves as the division director of Headache medicine at OSU.

What you’ll learn in this webcast

As a result of this educational activity, webcast participants will be able to:

  • Be able to diagnose migraine using ICHD3 criteria
  • Learn about the different treatments currently available for the acute and prophylactic treatment of migraine.
  • Learn about the diagnosis and management of trigeminal autonomic cephalgias
  • Learn about the diagnosis and management of other primary headache disorders.

You’ll also learn about the following:

  • Frequency of Migraines
  • Medication Overuse Headache
  • Prevention
  • Treatment Duration
  • Disability and FMLA

You can find this and many other MedNet21 programs on the OSU – CCME website.

Call our MedNet21 Program Manager at 614.293.3473 for more details about subscribing to MedNet21 as a hospital or as an individual. You can also e-mail him at derrick.freeman@osumc.edu.